|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001511,
umls-concept:C0003320,
umls-concept:C0005456,
umls-concept:C0014257,
umls-concept:C0024264,
umls-concept:C0078056,
umls-concept:C0205087,
umls-concept:C0205314,
umls-concept:C0332120,
umls-concept:C0679622,
umls-concept:C1416487,
umls-concept:C1421435,
umls-concept:C1514562,
umls-concept:C1524062,
umls-concept:C1880389,
umls-concept:C1883204,
umls-concept:C1883221,
umls-concept:C1948023
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1992-6-23
|
|
pubmed:abstractText |
Recent studies demonstrate that alternative splicing of mRNA from a single gene can produce two forms of vascular cell adhesion molecule 1 (VCAM-1): a six-immunoglobulin (Ig) domain form (VCAM-6D) and a seven-Ig domain form (VCAM-7D). Using a COS cell transient expression assay, we investigated whether VCAM-6D and VCAM-7D differ functionally in adhesion to the integrin VLA-4 (CD49d/CD29) on lymphoid cells. Binding of lymphoid cell lines and peripheral blood lymphocytes was completely blocked by VLA-4 monoclonal antibody (mAb) and one VCAM-1 mAb (4B9) to both VCAM-6D and VCAM-7D, whereas one VCAM-1 mAb (E1/6) completely blocked binding to VCAM-6D but only partially inhibited binding to VCAM-7D. We conclude that there is one VLA-4 binding site in the six Ig domains shared between VCAM-6D and VCAM-7D, and that the alternatively spliced domain 4 present in VCAM-7D provides a second VLA-4 binding site that is blocked by 4B9 but not the E1/6 mAb. We compared the inhibitory effects of anti-VCAM-1 and anti-VLA-4 mAbs on lymphoid cell adhesion to cultured human umbilical vein endothelial cells (HUVEC). The anti-VCAM-1 mAb 4B9 blocked the binding of PBL and lymphoid tumor cells to stimulated HUVEC better than the anti-VCAM-1 mAb E1/6. Because VCAM-7D is the predominant form of VCAM-1 expressed by stimulated endothelial cells, this difference in VCAM-1 mAb inhibition is attributed to lymphoid cell binding to VCAM-7D on stimulated HUVEC. Although the anti-VLA-4 mAb and anti-VCAM-1 mAb 4B9 equally inhibited PBL binding to stimulated HUVEC, mAb 4B9 inhibited the binding of two lymphoid cell lines significantly less than anti-VLA-4 mAb. Combination of 4B9 mAb with function-blocking antiserum to human fibronectin, a second known ligand for VLA-4, also failed to inhibit as much as anti-VLA-4 mAb. These findings suggest that adhesion of lymphoid cell lines through VLA-4 or other alpha 4 integrins may involve inducible counter-receptor(s) on endothelium distinct from either VCAM-1 or fibronectin. Time course experiments indicate that the fraction of alpha 4 integrin-dependent binding that can be blocked by anti-VCAM-1 mAb E1/6 rises and peaks within 2 h of tumor necrosis factor (TNF) stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1675157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1676048,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1691264,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1693380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1695646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1697486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1697696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1699207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1702807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1704649,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1707234,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1707873,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1709929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1710227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1713592,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1715583,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1715889,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1716464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1717579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1861722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1970514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1974032,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1980124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1990440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-1997648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2040616,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2083230,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2108206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2139716,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2142475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2188667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2219269,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2295088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2430809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2527858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2551146,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2588007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2688898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2825196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-2896596,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-3091693,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-3109455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-3134364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-3492556,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-3525675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-3555290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1375259-6984191
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules,
http://linkedlifedata.com/resource/pubmed/chemical/Integrins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Very Late Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Cell Adhesion Molecule-1
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-1007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
175
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1433-42
|
|
pubmed:dateRevised |
2010-9-7
|
|
pubmed:meshHeading |
|
